Lyrica

Pregabalin

Neuropathic pain in adults, including neuropathic pain associated w/ spinal cord injury. Generalized anxiety disorder (GAD) in adults. Management of fibromyalgia. Adjunctive therapy in adults w/ partial seizures, w/ or w/o secondary generalization.

Neuropathic pain Initially 150 mg daily, may be increased to 300 mg daily after an interval of 3-7 days. Max: 600 mg daily after an additional 7-day interval. Fibromyalgia Dose range: 300-450 mg daily given in 2 divided doses. Initially 75 mg bid, may be increased to 150 mg bid w/in 1 wk. May be further increased to 225 mg bid. Max: 600 mg daily after an additional wk. Epilepsy Initially 150 mg daily, may be increased to 300 mg daily after 1 wk. Max: 600 mg daily after an additional wk. GAD Dose range: 150-600 mg daily given in 2 or 3 divided doses. Initially 150 mg daily, may be increased to 300 mg daily after 1 wk. Following an additional wk, dose may be increased to 450 mg daily. Max: 600 mg daily after an additional wk. Renal impairment CrCl ≥60 mL/min Initially 150 mg daily in 2 or 3 divided doses. Max: 600 mg daily; ≥30-<60 mL/min Initially 75 mg daily given in 2 or 3 divided doses. Max: 300 mg daily; ≥15-<30 mL/min Initially 25-50 mg daily as a single or in 2 divided doses. Max: 150 mg daily; <15 mL/min Initially 25 mg daily as a single dose. Max: 75 mg daily. Supplementary dose following hemodialysis Initially 25 mg daily as a single dose, given immediately following every 4-hr hemodialysis. Max: 100 mg daily.

May be taken with or without food.

Hypersensitivity.

Discontinue immediately if symptoms of angioedema occur. Should not be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Adjust hypoglycemic medications in diabetic patients who gain wt. Associated w/ dizziness & somnolence which could increase the occurrence of accidental injury (fall). Loss of consciousness, confusion, mental impairment; transient visual blurring & other changes in visual acuity. W/drawal symptoms after discontinuation of short- & long-term treatment. Evaluate patients for history of drug abuse & observe for signs of misuse or abuse (eg, development of tolerance, dose escalation, drug-seeking behavior). Patients w/ severe CHF. Concomitant use w/ opioids. May influence the ability to drive or use machines. Women of childbearing potential must use effective contraception. Pregnancy. Not recommended during lactation. Childn <12 yr & adolescents. Elderly >65 yr.

Dizziness, somnolence. Nasopharyngitis; increased appetite; euphoric mood, confusion, irritability, depression, disorientation, insomnia, decreased libido; ataxia, abnormal coordination, tremor, dysarthria, amnesia, memory impairment, disturbance in attention, paresthesia, hypoesthesia, sedation, balance disorder, lethargy; blurred vision, diplopia; vertigo; vomiting, constipation, flatulence, abdominal distension, dry mouth; muscle cramp, arthralgia, back pain, limb pain, cervical spasm; peripheral edema, edema, abnormal gait, fall, feeling drunk/abnormal, fatigue; increased wt.

May potentiate effects of ethanol & lorazepam. Additive in the impairment of cognitive & gross motor function caused by oxycodone. Resp failure, coma & death w/ other CNS depressants. Reduced lower GIT function (eg, intestinal obstruction, paralytic ileus, constipation) w/ potentially constipation-producing medications eg, opioid analgesics.

Anticonvulsants / Drugs for Neuropathic Pain

N02BF02 - pregabalin ; Belongs to the class of gabapentinoids. Used to relieve pain and other conditions.

Rx